SCHEMBL89624

SCHEMBL89624

COCCC(=O)N1CC(C)(C)Oc2ccc(N(C(=O)[C@H]3CNC[C@@H](C(=O)NC(C)(C)c4ccccc4)C3)C3CC3)cc21

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
REN P00797 15/20 0.35
SSTR4 P31391 1/20 0.33
KCNH2 Q12809 4/20 0.31
ACKR3 P25106 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL89950 0.88 USP30 (0.31)
SCHEMBL89616 0.82 REN (0.53) REN
SCHEMBL1911397 0.81 REN (0.40) REN
SCHEMBL90241 0.78 REN (0.49) RENSSTR4KCNH2
SCHEMBL8237694 0.77 REN (0.46) RENSSTR4
SCHEMBL89679 0.76 REN (0.47) RENSSTR4
SCHEMBL8235471 0.73 REN (0.56) RENKCNH2
SCHEMBL90208 0.73 REN (0.56) RENKCNH2
SCHEMBL90491 0.72 REN (0.46) REN
SCHEMBL8238346 0.72 REN (0.54) RENKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 REN 1/4885SSTR4 905/4885KCNH2 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.